Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
NCT02772393 / 2015-004835-10: A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation

Recruiting
3
300
Europe, RoW
Paliperidone palmitate 3 month formulation (PP3M)
Janssen-Cilag Ltd., Janssen-Cilag International NV
Schizophrenia
12/17
03/18
NCT03485417: Substance Misuse To Psychosis for Stimulants

Recruiting
2/3
240
RoW
Aripiprazole, Paliperidone, Treatment as Usual
The University of Hong Kong, Queen Mary Hospital, Hong Kong, North District Hospital
Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis), Schizophrenia and Related Disorders, Stimulant Dependence, Stimulant Abuse, Pharmacotherapy
05/24
05/25

Download Options